48.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$48.40
Aprire:
$47.88
Volume 24 ore:
2.43M
Relative Volume:
1.06
Capitalizzazione di mercato:
$7.62B
Reddito:
$1.17B
Utile/perdita netta:
$150.71M
Rapporto P/E:
51.71
EPS:
0.94
Flusso di cassa netto:
$245.03M
1 W Prestazione:
+3.91%
1M Prestazione:
-3.72%
6M Prestazione:
-36.06%
1 anno Prestazione:
-37.03%
Bio Techne Corp Stock (TECH) Company Profile
Nome
Bio Techne Corp
Settore
Industria
Telefono
(612) 379-8854
Indirizzo
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Confronta TECH con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
TECH
Bio Techne Corp
|
48.61 | 7.63B | 1.17B | 150.71M | 245.03M | 0.94 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-30 | Iniziato | Wells Fargo | Overweight |
2025-04-09 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
2025-03-18 | Iniziato | Evercore ISI | Outperform |
2025-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
2024-02-08 | Iniziato | Scotiabank | Sector Outperform |
2024-02-02 | Downgrade | Stifel | Buy → Hold |
2023-12-07 | Iniziato | UBS | Buy |
2023-08-28 | Iniziato | William Blair | Outperform |
2023-01-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
2022-12-14 | Iniziato | Deutsche Bank | Buy |
2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
2022-12-07 | Iniziato | RBC Capital Mkts | Sector Perform |
2022-08-25 | Iniziato | Credit Suisse | Outperform |
2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
2021-09-15 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-03-08 | Aggiornamento | Stephens | Equal-Weight → Overweight |
2021-02-23 | Aggiornamento | Stifel | Hold → Buy |
2021-01-25 | Reiterato | The Benchmark Company | Buy |
2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
2020-09-30 | Iniziato | Atlantic Equities | Overweight |
2020-07-15 | Downgrade | Stephens | Overweight → Equal-Weight |
2020-05-27 | Downgrade | Stifel | Buy → Hold |
2020-05-14 | Iniziato | The Benchmark Company | Buy |
2020-01-08 | Ripresa | Stephens | Overweight |
2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
2020-01-07 | Iniziato | Citigroup | Neutral |
2019-11-15 | Iniziato | Stifel | Buy |
2019-07-02 | Aggiornamento | Janney | Neutral → Buy |
2019-01-14 | Aggiornamento | Stephens | Equal-Weight → Overweight |
2018-10-31 | Downgrade | Craig Hallum | Buy → Hold |
2018-10-17 | Iniziato | Goldman | Neutral |
2018-06-15 | Iniziato | Argus | Buy |
2017-07-13 | Iniziato | Wells Fargo | Market Perform |
2017-02-09 | Iniziato | Citigroup | Buy |
2017-01-18 | Iniziato | Deutsche Bank | Buy |
2016-11-10 | Ripresa | Leerink Partners | Outperform |
2015-01-21 | Reiterato | Robert W. Baird | Outperform |
2013-09-20 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
Mostra tutto
Bio Techne Corp Borsa (TECH) Ultime notizie
Wells Fargo Begins Coverage of Bio-Techne (TECH) Stock, Gives PT of $59 - Insider Monkey
Bio-Techne stock price target cut to $65 by Argus - Investing.com South Africa
Wells Fargo Initiates Coverage on Bio-Techne (TECH) with Overwei - GuruFocus
Wells Fargo starts Bio-Techne with Overweight, $59 target By Investing.com - Investing.com Canada
Demystifying Bio-Techne: Insights From 7 Analyst Reviews - Benzinga
Wells Fargo Initiates Coverage on Bio-Techne (TECH) with Overweight Rating | TECH Stock News - GuruFocus
Argus Adjusts Price Target on Bio-Techne to $65 From $90 - marketscreener.com
Wells Fargo starts Bio-Techne with Overweight, $59 target - Investing.com
Wells Fargo Initiates Bio-Techne at Overweight With $59 Price Target - marketscreener.com
Bio-Techne Corporation (TECH): A Bull Case Theory - Insider Monkey
Bio-Techne Corporation: An Insight Into The Pharmaceutical Market Dynamics & China's Economic & Regulatory Environment! - Smartkarma
Is Bio-Techne Stock The Right Pick For Your Portfolio Now? - Barchart.com
Is Bio-Techne Stock the Right Pick for Your Portfolio Now? - Nasdaq
Bio-Techne Sets Triple Conference Appearance: William Blair, Jefferies, and Goldman Sachs in June - Stock Titan
Bio-Techne to Present at Investor Conferences - Yahoo Finance
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MSN
Cetera Investment Advisers Sells 887 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Do Wall Street Analysts Like Bio-Techne Stock? - MSN
(TECH) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Bio-Techne (NASDAQ:TECH) Rating Increased to Buy at StockNews.com - Defense World
Ex-Dividend Reminder: Bio-Techne, First Hawaiian and Affiliated Managers Group - Nasdaq
Wednesday Sector Laggards: Healthcare, Materials - Nasdaq
What Makes Bio-Techne Corporation (TECH) a Compelling Addition? - Insider Monkey
ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA) - Quantisnow
Bio-Techne at BofA Securities 2025: Strategic Growth Amid Challenges By Investing.com - Investing.com Nigeria
Bio-Techne at BofA Securities 2025: Strategic Growth Amid Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - marketscreener.com
Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know - Yahoo Finance
Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025 - The Malaysian Reserve
Bio-Techne to Showcase Next-Generation Solutions for Gene and Ce - GuruFocus
UBS Group Cuts Bio-Techne (NASDAQ:TECH) Price Target to $70.00 - Defense World
When the Price of (TECH) Talks, People Listen - news.stocktradersdaily.com
StockNews.com Downgrades Bio-Techne (NASDAQ:TECH) to Hold - Defense World
Bio-Techne (TECH) Target Price Lowered to $70 by UBS Analyst | T - GuruFocus
UBS Adjusts Price Target on Bio-Techne to $70 From $95, Maintains Buy Rating - marketscreener.com
Bio-Techne outlines 2025 growth drivers with NIH uncertainty and strong Protein Sciences performance - MSN
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH) - GuruFocus
Bio-Techne, Kytopen collaborate on integrated cellular engineering workflow - TipRanks
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Sto - GuruFocus
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Stock News - GuruFocus
Benchmark Adjusts Bio-Techne Price Target to $75 From $95 - marketscreener.com
Bio-Techne (TECH): Benchmark Analyst Lowers Target Price but Maintains Buy Rating | TECH Stock News - GuruFocus
BIO-TECHNE (TECH): Analyst Maintains Hold Rating, Lowers Price Target | TECH Stock News - GuruFocus
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference - StreetInsider
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Eng - GuruFocus
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing | TECH Stock News - GuruFocus
Bio-Techne price target lowered to $63 from $72 at RBC Capital - TipRanks
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing - Stock Titan
Bio-Techne Corporation (NASDAQ:TECH) Q3 2025 Earnings Call Transcript - Insider Monkey
Bio-Techne Third Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference | TECH Stock News - GuruFocus
Bio Techne Corp Azioni (TECH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):